Effects of 1-Methylnicotinamide (MNA) on Exercise Capacity and Endothelial Response in Diabetic Mice
Open Access
- 26 June 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (6) , e0130908
Abstract
1-Methylnicotinamide (MNA), which was initially considered to be a biologically inactive endogenous metabolite of nicotinamide, has emerged as an anti-thrombotic and anti-inflammatory agent with the capacity to release prostacyclin (PGI2). In the present study, we characterized the effects of MNA on exercise capacity and the endothelial response to exercise in diabetic mice. Eight-week-old db/db mice were untreated or treated with MNA for 4 weeks (100 mg·kg-1), and their exercise capacity as well as NO- and PGI2-dependent response to endurance running were subsequently assessed. MNA treatment of db/db mice resulted in four-fold and three-fold elevation of urine concentrations of MNA and its metabolites (Met-2PY + Met-4PY), respectively (P1c concentration, fasting glucose concentration or lipid profile. However, insulin sensitivity was improved (P1α (difference between mean concentration in the sedentary and exercised groups) tended to increase, and post-exercise leukocytosis was substantially reduced in MNA-treated animals. In turn, the post-exercise fall in plasma concentration of nitrate was not affected by MNA. In conclusion, we demonstrated for the first time that MNA improves endurance exercise capacity in mice with diabetes, and may also decrease the cardiovascular risk of exercise.Keywords
This publication has 34 references indexed in Scilit:
- Exacerbation of endothelial dysfunction during the progression of diabetes: role of oxidative stressAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2012
- Therapeutic Potential of 1-Methylnicotinamide against Acute Gastric Lesions Induced by Stress: Role of Endogenous Prostacyclin and Sensory NervesThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Combination of the insulin sensitizer, pioglitazone, and the long‐acting GLP‐1 human analog, liraglutide, exerts potent synergistic glucose‐lowering efficacy in severely diabetic ZDF ratsDiabetes, Obesity and Metabolism, 2008
- The nitrate–nitrite–nitric oxide pathway in physiology and therapeuticsNature Reviews Drug Discovery, 2008
- 1‐Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti‐thrombotic activity mediated by a cyclooxygenase‐2/prostacyclin pathwayBritish Journal of Pharmacology, 2007
- Nitric oxide synthase-derived plasma nitrite predicts exercise capacityBritish Journal of Sports Medicine, 2007
- Hemodynamic Effects of Aerosolized Iloprost in Pulmonary Hypertension at Rest and During ExerciseChest, 2002
- Stimulation of Prostacyclin Synthesis by Physical Exercise in Type I DiabetesDiabetes Care, 1989
- Effects of iloprost, a stable prostacyclin analog, on exercise capacity and platelet aggregation in stable angina pectorisThe American Journal of Cardiology, 1986
- RELEASE OF PROSTACYCLIN IN VIVO AND ITS ROLE IN MANThe Lancet, 1983